ItalyTwo clinical trials based on stem cell-derived neuron transplants have completed twelve months of observation in patients with Parkinson’s disease, providing new data on the safety of these procedures and the potential of dopamine-producing cells to replace those destroyed by the disease. The results were presented at the annual meeting of the International Society for Stem Cell Research (ISSCR) and involve two distinct approaches: the STEM-PD study led by Malin Parmar at the University of Lund (Sweden), which uses standardized human pluripotent stem cell-derived neurons, and the first phase I/IIa trial led by Jeanne Loring at Scripps Research (USA), developed by biotech Aspen Neuroscience, which employs patient-derived cells. Both studies will soon be published in Nature Medicine. Parkinson’s is a neurodegenerative disorder caused by progressive loss of dopamine-producing neurons, and current treatments like levodopa manage symptoms but do not halt progression or restore lost nerve cells. The STEM-PD study involved moderately advanced Parkinson’s patients who continued to show symptoms despite optimized pharmacological treatment. Patients received transplants of dopaminergic nerve
Bias read (Center): The article presents scientific research on stem cell therapy for Parkinson’s disease without overt ideological framing. It describes both studies objectively, highlighting their methodologies, outcomes, and implications without taking a clear stance on policy, ethics, or societal impact. While the醫
